Richard J. Daly - 02 Jan 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
President and CEO, Director
Signature
/s/ Richard J. Daly
Issuer symbol
CPRX
Transactions as of
02 Jan 2025
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 17:00:13 UTC
Previous filing
31 Dec 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +42,105 +18% 277,938 02 Jan 2025 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -10,600 -3.8% 267,338 02 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -42,105 -1.8% $0.000000 2,238,753 02 Jan 2025 Common Stock 42,105 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3 Derivative securities vest in equal tranches, 1/5th each on January 1, 2025, 2026, 2027, 2028 and 2029.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on January 2, 2025.